Tyrosine kinase

Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED

Retrieved on: 
Friday, February 2, 2024
Partnership, Atopic dermatitis, HCM, BTK, Tyrosine kinase, SAN, Alopecia areata, Drug development, I&I, Pharmaceutical industry

The option was exercised pursuant to a collaboration between Inmagene and HUTCHMED (Nasdaq/AIM:HCM) announced in 2021 to develop and commercialize a portfolio of drug candidates for I&I diseases.

Key Points: 
  • The option was exercised pursuant to a collaboration between Inmagene and HUTCHMED (Nasdaq/AIM:HCM) announced in 2021 to develop and commercialize a portfolio of drug candidates for I&I diseases.
  • "Our strategic partnership with HUTCHMED has allowed us to take IMG-007 and IMG-004, two assets with best-in-class potential, from pre-clinical to clinical development," said Jonathan Wang, Ph.D., Chief Executive Officer of Inmagene.
  • "Obtaining the worldwide exclusive rights is another step forward in our journey to become a global leader in novel drug development for I&I diseases."
  • IMG-007 is being evaluated in Phase 2a studies in two indications: moderate-to-severe atopic dermatitis and alopecia areata.

Florida Cancer Specialists & Research Institute Contributing to Cutting-Edge Advancements in Hematology Science

Retrieved on: 
Wednesday, December 13, 2023
Annual Reviews (publisher), ASH, BTK, Research, Bortezomib, Omicron, Conference, Bangladesh Technical Education Board, Poster, Mantle cell lymphoma, SLL, Risk, Science, Abstract, Drug development, Tyrosine kinase, Society, B-cell lymphoma, FACP, Rituximab, Reversibility, Delta, Phase, Nivolumab, Hospital, Safety, DRD, MCL, FCS, FDA, Lymphocytosis, Pivotal trial, Chronic lymphocytic leukemia, Meta-analysis, Artery, Bias, Coronary thrombosis, NHL, CLL, Pharmaceutical industry, Dietary supplement, Vaccine, Birth control, Incidence, Patient, Dexamethasone, Lenalidomide, Hematology, Relapse, Dacarbazine, MD, Doxorubicin

FORT MYERS, Fla., Dec. 13, 2023 /PRNewswire/ -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) was presented in the cutting-edge advancements being shared at the American Society of Hematology (ASH) 65th Annual Meeting and Exposition in San Diego on Dec. 9 - 12, 2023. Scientific abstracts submitted by FCS hematologists and medical oncologists were among the 7,000 accepted submissions selected through an extensive peer review process.

Key Points: 
  • FORT MYERS, Fla., Dec. 13, 2023 /PRNewswire/ -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) was presented in the cutting-edge advancements being shared at the American Society of Hematology (ASH) 65th Annual Meeting and Exposition in San Diego on Dec. 9 - 12, 2023.
  • Scientific abstracts submitted by FCS hematologists and medical oncologists were among the 7,000 accepted submissions selected through an extensive peer review process.
  • Pirtobrutinib has also been approved for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
  • Once again, FCS is proud to have a strong presence, sharing the latest and most promising research and science that is moving the field forward."

Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Eli Lilly and Company, Experiment, NYSE, Reversibility, Prior, SLL, Use, LLY, Safety, Chronic lymphocytic leukemia, Mantle cell lymphoma, Covalent bond, Medication discontinuation, Society, ASH, Lymphocytosis, Tyrosine kinase, CLL, Poster, MCL, Lymphoid leukemia, Therapy, BTK, Manchester Grand Hyatt Hotel, Pharmaceutical industry, Vaccine, Hotel, Patient

INDIANAPOLIS, Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego.

Key Points: 
  • INDIANAPOLIS, Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego.
  • The presentations will provide updated, longer follow-up clinical safety and efficacy data for approved and investigational uses of pirtobrutinib from the ongoing Phase 1/2 BRUIN study in multiple B-cell malignancies.
  • In mantle cell lymphoma (MCL), an oral presentation will provide updated safety and efficacy results of pirtobrutinib in all patients, including those with biologically high-risk relapsed or refractory MCL.
  • Additionally, poster presentations will provide data on the clinical impact of pirtobrutinib following cBTKi treatment across other B-cell malignancies.

Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLC

Retrieved on: 
Wednesday, May 31, 2023
AACR, HER2, Hope, TKI, NSCLC, Yuhan, Lung cancer, Corporation, Patient, Tyrosine kinase, Cryptocurrency, Pharmaceutical industry

SEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, 'JIN-A04'.

Key Points: 
  • SEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, 'JIN-A04'.
  • JIN-A04 is an oral TKI targeting non-small cell lung cancer carrying HER2 mutations, and there is currently no approved oral drug approved to date.
  • Anna Jo, CEO of J INTS BIO, said, "JIN-A04 is expected to be a hope for NSCLC patients with 'HER2 Exon20 insertion' mutations."
  • Meanwhile, Yuhan invested 1.5 million dollars in J INTS BIO in 2021 and 2022, respectively, and holds a 14.8% stake in the company.

Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLC

Retrieved on: 
Wednesday, May 31, 2023
AACR, HER2, Hope, TKI, Multimedia, NSCLC, Yuhan, Lung cancer, Corporation, Patient, Tyrosine kinase, Cryptocurrency, Pharmaceutical industry

SEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, 'JIN-A04'.

Key Points: 
  • SEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, 'JIN-A04'.
  • JIN-A04 is an oral TKI targeting non-small cell lung cancer carrying HER2 mutations, and there is currently no approved oral drug approved to date.
  • Anna Jo, CEO of J INTS BIO, said, "JIN-A04 is expected to be a hope for NSCLC patients with 'HER2 Exon20 insertion' mutations."
  • Meanwhile, Yuhan invested 1.5 million dollars in J INTS BIO in 2021 and 2022, respectively, and holds a 14.8% stake in the company.

Florida Cancer Specialists & Research Institute Research Breakthroughs Presented at Global Hematology Gathering

Retrieved on: 
Tuesday, December 13, 2022
Chronic lymphocytic leukemia, Role, ASH, AML, American Society of Clinical Oncology, Research, COVID-19, Menin, Hematology, Stanford University, Acute leukemia, Diagnosis, FACP, Prednisone, Health, University of Florida Cancer and Genetics Research Complex, Reversibility, Rituximab, Meta-analysis, Doctor of Pharmacy, Daratumumab, Society, Duke, Tyrosine kinase, ASCO, Hope, News, Quality of life, FCS, BTK, Safety, U.S. News & World Report, Immunotherapy, Drug development, Phase, Physician, Poster, Memorial Sloan Kettering Cancer Center, Covalent bond, Monroe Dunaway Anderson, Harvard University, Pharmaceutical industry, MD, Relapse, Vincristine, Acalabrutinib, Cyclophosphamide, Patient, Doxorubicin, Venous thrombosis

Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) that is contributing to global advancements in the diagnosis and treatment of blood diseases was presented at the American Society of Hematology (ASH) 64th Annual Meeting and Exposition in New Orleans, Louisiana on Dec. 10 – 13, 2022.

Key Points: 
  • Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) that is contributing to global advancements in the diagnosis and treatment of blood diseases was presented at the American Society of Hematology (ASH) 64th Annual Meeting and Exposition in New Orleans, Louisiana on Dec. 10 – 13, 2022.
  • “The abstracts being presented with FCS participation represent important, novel research and are considered among the best in the field of hematology,” said FCS President & Managing Physician Michael Diaz, MD .
  • Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida.
  • Over the past 5 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.

The Oncology Institute Enrolls Nation’s First Two Patients in a Phase 3 Open-Label, Randomized Clinical Trial of Pirtobrutinib

Retrieved on: 
Thursday, September 29, 2022
BTK, Ibrutinib, Medical director, FDA, Principal, Company, Population, American Oncology Institute, Patient, Clinical trial, Tyrosine kinase, Founder, CLL, NASDAQ, Research, GLOBE, TOI, Eli Lilly, Principal investigator, Pharmaceutical industry, Medical device, Medical imaging

Pirtobrutinib (LOXO-305) is currently in clinical trial phase, whereas Ibrutinib has been available in the market since 2013.

Key Points: 
  • Pirtobrutinib (LOXO-305) is currently in clinical trial phase, whereas Ibrutinib has been available in the market since 2013.
  • Eli Lilly and Company serves as the sponsor of this clinical trial.
  • Pirtobrutinib and Ibrutinib are both oral treatments that bind to the Bruton Tyrosine Kinase (BTK) protein to inhibit its activity.
  • We at TOI are extremely proud of our role in this important clinical trial, says Dr. Yale Podnos, Chief Medical Officer of The Oncology Institute.

American Oncology Network Physicians Research is Well Represented at the ASH Annual Meeting & Exposition

Retrieved on: 
Thursday, December 16, 2021
Relapse, Lymphatic system, AON, Hematology, Efficacy, Physician, Abstract, Center, Hematology-Oncology and Stem Cell Transplantation Research Center, LLC, 2021 Essex County Council election, Refractory, Research, ICT, Exposition, Pathology, Society, BTK, Neutralizing antibody, Degenerative disease, GLOBE, ASH, Tyrosine kinase, Abstract (summary), Practitioner, Steroid, Hereditary haemochromatosis, Pharmaceutical industry, Medicine, Safety, Cancer, Patient

Fort Myers, Fla., Dec. 16, 2021 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) is pleased to announce that eight research studies co-authored by AON physicians were presented at the American Society of Hematology (ASH) Annual Meeting & Exposition , held December 11-14, 2021.

Key Points: 
  • Fort Myers, Fla., Dec. 16, 2021 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) is pleased to announce that eight research studies co-authored by AON physicians were presented at the American Society of Hematology (ASH) Annual Meeting & Exposition , held December 11-14, 2021.
  • Abstracts submitted for oral and poster presentations at the ASH annual meeting represent important, novel research in the field and are considered the best of the thousands of abstracts submitted.
  • American Oncology Network, LLC (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology.
  • Launched in 2018, the rapidly growing AON network represents 105 physicians and 79 nurse practitioners and physician assistants practicing across 16 states.

EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting

Retrieved on: 
Tuesday, October 12, 2021
ACT, Safety, Diabetic retinopathy, Cancer, Uveitis, Aqueous humour, Therapy, Technology, Nasdaq, Company, Twitter, Macular edema, Intellectual property, Incidence, Inflammation, Patient, Severe cognitive impairment, COVID-19, Retina, LinkedIn, TKI, FDA, Șaeș, U.S. Securities and Exchange Commission, Visual acuity, Macular degeneration, Eye, Clinical trial, Annual general meeting, CST, NASDAQ, Central retinal vein occlusion, AMD, AES, CALM, IOP, Private Securities Litigation Reform Act, Forward-looking statement, SAFE, Risk, Retinal detachment, GLOBE, THE, Diagnosis, Industry, Endophthalmitis, Society, ASRS, Interim, FAI, Tyrosine kinase, AC, Compliance, Swelling, Pharmaceutical industry

WATERTOWN, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced positive interim safety data from its Phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD), and preliminary results from YUTIQ® CALM, a real-world registry study of the fluocinolone acetonide intravitreal (FAi) implant 0.18 mg in chronic noninfectious posterior uveitis. The two studies were presented in a Paper-On-Demand and an ePoster Presentation, respectively, at the American Society of Retina Specialists (ASRS) 39th Annual Meeting held October 8 – 12, 2021.

Key Points: 
  • The two studies were presented in a Paper-On-Demand and an ePoster Presentation, respectively, at the American Society of Retina Specialists (ASRS) 39th Annual Meeting held October 8 12, 2021.
  • The study is ongoing, and all patients were previously treated with standard of care anti-VEGF therapies.
  • Key safety observations through at least 3-months post-dosing for all patients include that no serious adverse events (SAEs), ocular or systemic, were reported.
  • The ongoing YUTIQ CALM real-world registry study is collecting data on patients who have received the fluocinolone acetonide intravitreal implant 0.18 mg.

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer

Retrieved on: 
Wednesday, July 28, 2021
Enzymes, Tyrosine kinase receptors, Companies, Tyrosine kinase inhibitor, AstraZeneca, Tyrosine kinase, C-Met, TKI, Quinazolines, Pyrrolidines

Patients whose tumors harbor MET amplification were treated with ORPATHYS monotherapy, reporting an ORR of 50% (10/20, 95% CI: 28.0, 71.9).

Key Points: 
  • Patients whose tumors harbor MET amplification were treated with ORPATHYS monotherapy, reporting an ORR of 50% (10/20, 95% CI: 28.0, 71.9).
  • ORPATHYS is an oral, potent, and highly selective MET tyrosine kinase inhibitor (TKI) that has demonstrated clinical activity in advanced solid tumors.
  • In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing agreement to jointly develop and commercialize ORPATHYS.
  • Joint development in China is led by HUTCHMED, while AstraZeneca leads development outside of China.